180 results about "Triazene" patented technology

The triazinewherein Ar1, Ar2, Ar3, and Ar4 are each independently an aryl; R1 and R2 are substituents selected from the group consisting of hydrogen, an alkyl, an aryl, an alkoxy, a halogen atom, and a cyano; R3 and R4 are each a divalent group L selected from the group consisting of -C(R'R'')-, alkylene, an oxygen atom, a sulfur atom, and -Si(R'R'')-, wherein R' and R'' are selected from the group consisting of hydrogen, alkyl, alkoxy, and aryl.

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001" / >(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup

The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

A new light-emitting device utilizing phosphorescence is provided. Further, an electronic device and a lighting device which utilize phosphorescence are provided. One embodiment of the present invention is a light-emitting device including a phosphorescent organometallic iridium complex comprising iridium and either pyrimidine having an aryl group at the 4-position or 1,3,5-triazine having an aryl group at the 2-position. One of nitrogen in the pyrimidine or 1,3,5-triazine is coordinated to the iridium. Also, each of the pyrimidine and 1,3,5-triazine has a substituent such as an alkyl group or an aryl group. Further the ortho position of the aryl group which is bonded to the 4-position of the pyrimidine or the 2-position of the 1,3,5-triazine is bonded to the iridium.

The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.

The present invention relates to compounds of the Formulaand pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.

The invention belongs to the field of photocatalyst application of organic semiconductors and in particular relates to application of a heteroatom-containing triazine covalent organic framework material in photocatalysis. The heteroatom-containing triazine covalent organic framework material serves as a photocatalyst. The preparation method comprises the following steps: introducing heteroatoms through heterocyclic aldehyde group monomers, carrying out a condensation polymerization reaction with binary or poly-element amidino compounds in the presence of a basic catalyst, thereby obtaining theproduct. The material serves as the photocatalyst, and is capable of degrading organic pollutants in water and producing hydrogen under light conditions by virtue of water splitting. According to themethods, the heteroatom-containing triazine covalent organic framework material is introduced to serve as the photocatalyst, and is high in catalytic efficiency, high in applicability and suitable for large-scale application.

The invention relates to a 2-arylaminopyridine, pyrimidine or triazine derivative and a preparation method and application thereof. The 2-arylaminopyridines, pyrimidines or triazine derivatives may act on certain mutant forms of epidermal growth factor receptors such as L858R activating mutants, delE746_A750 mutants, Exonl9 deletion activating mutants and T790M drug resistant mutants , for use in the treatment and prevention of diseases and conditions. The 2-arylaminopyridine, pyrimidine or triazine derivatives are useful for the treatment and prevention of cancer. The present invention also relates to pharmaceutical compositions comprising 2-arylaminopyridines, pyrimidines or triazine derivatives, intermediates useful in the preparation of 2-arylaminopyridines, pyrimidines or triazine derivatives, and the use of 2-arylamino Pyridine, pyrimidine or triazine derivatives in the treatment of diseases mediated by various forms of EGFR.

This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly Cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly Cancer.

The invention relates to a triazine compound. The structural formula of the triazine compound is as shown in formula I, wherein L is substituted or non-substituted C6-C24 arylidene; n is 0 or 1; Py is substituted or non-substituted C3-C24 nitrogen-containing heterocyclic groups or nitrogen-containing heterocyclic condensation groups; Ac1 and Ac2 are substituted or non-substituted C12-C48 nitrogen-containing heterocyclic condensation groups; Ac1 and Ac2 can be identical ort different. The invention further relates to a light-emitting device containing the triazine compound. When two nitrogen-containing heterocyclic condensation groups are connected with a triazine group, certain angles are formed between the nitrogen-containing heterocyclic condensation groups and the triazine group due to steric hindrance, and TADF design is achieved.

A new light-emitting device utilizing phosphorescence is provided. Further, an electronic device and a lighting device which utilize phosphorescence are provided. One embodiment of the present invention is a light-emitting device including a phosphorescent organometallic iridium complex comprising iridium and either pyrimidine having an aryl group at the 4-position or 1,3,5-triazine having an aryl group at the 2-position. One of nitrogen in the pyrimidine or 1,3,5-triazine is coordinated to the iridium. Also, each of the pyrimidine and 1,3,5-triazine has a substituent such as an alkyl group or an aryl group. Further the ortho position of the aryl group which is bonded to the 4-position of the pyrimidine or the 2-position of the 1,3,5-triazine is bonded to the iridium.

The invention provides a novel compound which is represented by the formula (I), wherein the R1 to R5 are independently selected from a C1-C20 aliphatic alkyl group or a C6-C20 aromatic group; the Ar is selected from: a C4-C30 aromatic ring, a C4-C30 N-containing heterocycle, a C4-C30 condensed heterocyclic aromatic hydrocarbon, a C4-C30 aromatic amino group, or a C4-C30 aromatic oxy group; n is 1 or 2; A1 to A4 represent N atoms or C atoms, when the A1 and A3 represent N atoms at the same time, the A2 and A4 represent C atoms; or when the A1 and A4 represent N atoms at the same time, the A2 and A3 represent C atoms; or when the A2 and A4 represent N atoms at the same time, the A1 and A3 represent C atoms; or when the A3 and A4 represent N atoms at the same time, the A1 and A2 represent C atoms; or when the A1, A3, and A 4 represent N atoms at the same time, the A2 represents a C atom; and L represents a single bond, or a C6-C10 aromatic ring, or a C4-C10 N-containing heterocycle. The compounds are used as an electron transmission layer material or a luminous main material in organic electroluminescence devices.

The invention provides a synthesis method of a porous organic covalent frame material with a triazine structure. The synthesis method comprises the steps of in a 1,4-dioxane-mesitylene-acetic acid mixed solvent, carrying out solvothermal reaction on p-phenylenediamine and cyanuric chloride for 70 to 72h at 115 to 120 DEG C, repetitively washing a product through tetrahydrofuran and methyl alcohol,drying, grinding, and obtaining earthy yellow powder which is a target object. The synthesis method provided by the invention has the characteristics of cheap and easy-to-get raw materials, simple synthesis process, mild reaction conditions, low synthesis cost, high yield and the like; the synthesized COF material is large in specific surface area, low in density, and high in nitrogen content, and has a better application prospect in the fields of adsorption, drug release, photoelectricity functions, catalysis and the like.

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II):wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

The present invention relates to a metal phthalocyanine fiber-supported metal phthalocyanine having catalytic activity and preparation method, said metal phthalocyanine with fiber or fabric through covalent bond conjoint mode combining to form supported fiber having catalytic activity. The used etal phthalocyanine is transition metal ion such as characterized in having the structure of formula 1, in which M is a Fe,Co,Cu,Mn,Rb,Al,Zn and Ni; R1,R2,R3,R4 each can be H, any of the five in formular (1), and others are all H, the construction of the radical R5 can be -NH2, -NHCOCH3, -NHSO3Na, and -NHSO3H. Said preparation method is selecting metal phthalocyanine as reactive group having triazine structure under pH 8- 11 reaction temperature 45 -95 degree centigrade condition, adding fiber or fabric to finite concentration reactivity metal phthalocyanine aqueous solution, continuously stirring, after reaction taking out fiber or fabric and respectively to make caustic washing and water washing, drying to obtain fiber-supported metal phthalocyanine or fabric. Said invention has simple equipment, easy to operate etc advantages.

There is provided a curable fluoroelastomer composition comprisingi. a first compound which comprising repeating units derived from a fluorinated olefin and further comprising at least one functional group,ii. a second compound comprising repeating units selected from (—C4F8O—), (—C2F4O—) or (—CF2O) or a combination thereof and further containing at least one functional group capable of reacting with the at least one functional group of the first compound either directly or in the presence of a curing compound to form a triazine unit,wherein the composition after curing by forming triazine units has a glass transition temperature of less than −60° C. Also provided are shaped articles comprising the cured compositions, methods of making cured compositions and methods for making shaped articles.

The invention relates to triazine-containing benzoxazine, a triazine-containing benzoxazine polymer, and a preparation method thereof. The preparation method is characterized by: adopting cyanophenol as a raw material; adopting trifluoromethanesulfonic acid or trifluoroacetic acid as a catalyst; synthesizing triazine-containing trihydric phenol (TP for short) in dichloromethane or chloroform or acetone at a common temperature; adopting the synthesized TP, formaldehyde and aminated compounds as reaction raw materials; adopting a alkali as the catalyst, and carrying out a reaction in a alcohol solvent or a ether solvent to synthesize a series of triazine-containing polycyclic benzoxazine monomers (BZ for short) which have not been reported; heating the BZ to carry out a ring-opening polymerization to form polybenzoxazine (PBZ for short). A structural formula of the monomer BZ is shown as follow, substituents R are shown in the specification. The synthesized novel monomer provided by the present invention contains a triazine ring structure, such that the triazine content in the PBZ resin can be substantially raised so as to notably improve heat resistance, residual carbon rate, fire resistance property and wave transmission property of the PBZ.

A method for scavenging amines within polymeric compositions of matter comprising the step of adding to a polymeric composition of matter at least one triazine compound, wherein said triazine compound is defined according to the formula:where X is selected from the group consisting of hydrogen, halides, amines, and organic groups having from 1 to about 20 carbon atoms, Y is selected from the group consisting of halides, alkoxy derivatives, amine derivatives, aryloxy derivatives, and urea derivatives, with the proviso that the substituent Y is displacable by a reaction with a secondary amine, and Z is selected from the group consisting of alkoxy derivatives, amino derivatives, aryloxy derivatives, and urea derivatives, with the proviso that the substituent Z is displacable by a reaction with a secondary amine.

A color filter has a filter segment. The filter segment is formed by means of a color composition for color filter. The color composition for color filter includes: a phosphate-ester series pigment dispersant; a pigment derivatives having a certain alkali-base; at least one alkali-base-containing derivatives selected from pigment derivatives, a Anthraquinone derivatives and a triazine derivatives; a pigment carrier; and a pigment.

Preparations of novel molecular transporter compositions and their use for transporting bioactive substances into cells in living animals are disclosed. To afford in vivo delivery, the composition is covalently linked to the bioactive substance and the resultant composite structure is introduced into the subject. The transporter composition includes multiple guanidine moieties on a dendrimeric scaffold having a triazine core.

The invention discloses a 1,3,5-triazinyl nanopore organic aromatic heterocyclic polymer and a preparation method thereof. The 1,3,5-triazinyl nanopore organic aromatic heterocyclic polymer is prepared from 2,4,6- trichlorine-1,3,5-triazine andaromatic compounds through Friedel-Crafts reaction in the presence of catalyst of lewis acid. The prepared polymer has controllable pore size and high specific surface area as well as CO2 capturing ability, good heat stability and chemical stability. The polymer has an important application value in gas storing, especially in CO2 capturing and has a wide application prospect in many fields such as field of catalytic supports and selective separation of ion.

Methods for fabricating triazene-based graphitic carbon nitride films are provided. A substrate can be coated with silk fibroin, submerged in the central zone of plasma, and provided with microwave power. The substrate can then be dried to give a triazene-based graphitic carbon nitride film. Methods of the subject invention can be easily scaled up to industrial levels and produce triazene-based graphitic carbon nitride films that show excellent electrical properties as anodes in lithium-ion batteries.

Provided herein are formulations, methods and substituted tetrahydrofuranyl- pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-fj[i,2,4]triazine-4-amine compounds.

The invention discloses a compound represented by a formula (I) and application thereof to chicken coccidiosis disease control. The compound represented by the formula (I) is obtained by condensation of a compound represented by a formula (II) or sodium phenolate thereof with a compound represented by a formula (III) under the alkaline condition, wherein a substituent group x in the compound represented by the formula (III) is halogen. The compound represented by the formula (I) has the effects of preventing and treating a chicken coccidiosis disease, and has good chicken coccidiosis resisting activity when in concentration of 0.5-20mg / kg.

A carbon black aqueous dispersion that is suitable as an aqueous black ink for inkjet printers, and a method of producing the same are disclosed. A surface-treated carbon black aqueous dispersion includes an aqueous medium and surface-treated carbon black that is dispersed in the aqueous medium, the surface-treated carbon black having been chemically modified by causing a hydrophilic surface functional group of the carbon black and an amino group-containing compound to undergo a dehydration-condensation reaction in the presence of a triazine condensing agent to form an amide bond. A method of producing a surface-treated carbon black aqueous dispersion includes oxidizing carbon black to produce a hydrophilic surface functional group, dispersing the carbon black in an aqueous medium to obtain an aqueous medium dispersion, adding an amino group-containing compound and a triazine condensing agent to the aqueous medium dispersion, causing the hydrophilic surface functional group of the carbon black and the amino group-containing compound to undergo a dehydration-condensation reaction by stirring the aqueous medium dispersion at room temperature, and removing large particles, unreacted amino group-containing compound, a decomposition product of the triazine condensing agent, and unreacted triazine condensing agent, followed by neutralization, purification, and concentration.